JP7614841B2 - 抗原性呼吸器合胞体ウイルスポリペプチド - Google Patents
抗原性呼吸器合胞体ウイルスポリペプチド Download PDFInfo
- Publication number
- JP7614841B2 JP7614841B2 JP2020554448A JP2020554448A JP7614841B2 JP 7614841 B2 JP7614841 B2 JP 7614841B2 JP 2020554448 A JP2020554448 A JP 2020554448A JP 2020554448 A JP2020554448 A JP 2020554448A JP 7614841 B2 JP7614841 B2 JP 7614841B2
- Authority
- JP
- Japan
- Prior art keywords
- rsv
- polypeptide
- ferritin
- seq
- antigenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024153695A JP2024170566A (ja) | 2018-04-03 | 2024-09-06 | 抗原性呼吸器合胞体ウイルスポリペプチド |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862652199P | 2018-04-03 | 2018-04-03 | |
| US62/652,199 | 2018-04-03 | ||
| PCT/US2019/025387 WO2019195291A1 (en) | 2018-04-03 | 2019-04-02 | Antigenic respiratory syncytial virus polypeptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024153695A Division JP2024170566A (ja) | 2018-04-03 | 2024-09-06 | 抗原性呼吸器合胞体ウイルスポリペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021519597A JP2021519597A (ja) | 2021-08-12 |
| JP2021519597A5 JP2021519597A5 (cg-RX-API-DMAC7.html) | 2022-04-07 |
| JP7614841B2 true JP7614841B2 (ja) | 2025-01-16 |
Family
ID=66182672
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020554448A Active JP7614841B2 (ja) | 2018-04-03 | 2019-04-02 | 抗原性呼吸器合胞体ウイルスポリペプチド |
| JP2024153695A Pending JP2024170566A (ja) | 2018-04-03 | 2024-09-06 | 抗原性呼吸器合胞体ウイルスポリペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024153695A Pending JP2024170566A (ja) | 2018-04-03 | 2024-09-06 | 抗原性呼吸器合胞体ウイルスポリペプチド |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12071454B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3773704A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7614841B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102964264B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112512567A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019247034B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020019938A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3095175A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020010199A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019195291A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3773698A1 (en) | 2018-04-03 | 2021-02-17 | Sanofi | Ferritin proteins |
| CN112512566A (zh) | 2018-04-03 | 2021-03-16 | 赛诺菲 | 抗原性爱泼斯坦-巴尔病毒多肽 |
| JP7614841B2 (ja) | 2018-04-03 | 2025-01-16 | サノフイ | 抗原性呼吸器合胞体ウイルスポリペプチド |
| US20230302112A1 (en) | 2021-11-05 | 2023-09-28 | Sanofi | Respiratory synctial virus rna vaccine |
| WO2023201222A1 (en) * | 2022-04-11 | 2023-10-19 | Vanderbilt University | Ferritin nanoparticles and methods of use thereof |
| WO2024041772A1 (en) * | 2022-08-22 | 2024-02-29 | Glaxosmithkline Biologicals Sa | Rsv-f proteins |
| WO2024078597A1 (en) * | 2022-10-13 | 2024-04-18 | Rvac Medicines (Us) , Inc. | Rsv f protein variants and uses thereof |
| KR20250099727A (ko) | 2022-11-04 | 2025-07-02 | 사노피 파스퇴르 인크 | 호흡기 세포융합 바이러스 rna 백신접종 |
| US20250009865A1 (en) | 2023-05-10 | 2025-01-09 | Sanofi | Combination respiratory mrna vaccines |
| CN122180699A (zh) * | 2023-08-03 | 2026-06-09 | 广州宾和企业管理合伙企业(有限合伙) | 修饰的呼吸道合胞病毒f蛋白及其用途 |
| WO2025092933A1 (zh) * | 2023-10-31 | 2025-05-08 | 上海蓝鹊生物医药有限公司 | 一种rsv抗原、核酸、重组表达载体、药物组合物及其应用 |
| CN117586359A (zh) * | 2024-01-19 | 2024-02-23 | 北京安百胜生物科技有限公司 | 一种具有免疫原性的呼吸道合胞病毒(rsv)多肽 |
| CN120099235A (zh) * | 2025-05-09 | 2025-06-06 | 北京华诺泰生物医药科技有限公司 | 一种微生物发酵工艺的优化方法及装置 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006104216A (ja) | 1993-08-20 | 2006-04-20 | Government Of The Us Of America As Represented By The Secretary Department Of Health & Human Service | 植物、動物、およびヒトのワクチンとして並びに免疫療法に有用な抗体の免疫優性エピトープの弱化 |
| JP2014530003A (ja) | 2011-09-20 | 2014-11-17 | モウント シナイ スクール オフ メディシネ | インフルエンザウイルスワクチン及びその使用 |
| JP2016519658A (ja) | 2013-03-13 | 2016-07-07 | アメリカ合衆国 | 融合前rsvfタンパク質およびそれらの使用 |
| WO2017172890A1 (en) | 2016-03-29 | 2017-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Substitutions-modified prefusion rsv f proteins and their use |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9407182A (pt) | 1993-08-06 | 1996-09-17 | Connaught Lab | Composição imunogênica processo de preparo de composição não-imunopotencializadora imunogênica processo para determinar a presença de anticorpos estojo para diagnóstico para determinar a presença de anticorpos e virus sincicial respiratório humano inativado purificado |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| AU713040B2 (en) | 1994-07-15 | 1999-11-18 | University Of Iowa Research Foundation, The | Immunomodulatory oligonucleotides |
| CA2281838A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| EP1003531B1 (en) | 1997-05-20 | 2007-08-22 | Ottawa Health Research Institute | Processes for preparing nucleic acid constructs |
| US6218371B1 (en) | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| WO2001075436A1 (en) | 2000-04-03 | 2001-10-11 | Board Of Trustees Of The Leland Stanford Junior University | A method for protein structure alignment |
| EP1311540B1 (en) | 2000-08-18 | 2007-12-19 | Research Foundation Of State University Of New York | Altered ospa of borrelia burgdorferi |
| US7097841B2 (en) | 2002-05-10 | 2006-08-29 | New Century Pharmaceuticals, Inc. | Ferritin fusion proteins for use in vaccines and other applications |
| US7774185B2 (en) | 2004-09-14 | 2010-08-10 | International Business Machines Corporation | Protein structure alignment using cellular automata |
| EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| US20100285051A1 (en) | 2007-12-21 | 2010-11-11 | Dominique Ingrid Lemoine | Vaccine |
| US8563002B2 (en) | 2007-12-24 | 2013-10-22 | Glaxosmithkline Biologicals, S.A. | Recombinant RSV antigens |
| US20110117131A1 (en) | 2008-04-09 | 2011-05-19 | Ning Huang | Production of OspA for Lyme Disease Control |
| ES2987238T3 (es) | 2008-12-09 | 2024-11-14 | Novavax Inc | Proteínas F del RSV modificadas y métodos de su uso |
| EP4183412B1 (en) | 2009-07-15 | 2024-08-14 | GlaxoSmithKline Biologicals SA | Rsv f protein compositions and methods for making same |
| US8623375B2 (en) | 2010-05-14 | 2014-01-07 | Baxter International Inc. | Chimeric OspA genes, proteins, and methods of use thereof |
| WO2012006180A1 (en) | 2010-06-29 | 2012-01-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv immunogens |
| US20140186371A1 (en) | 2011-04-07 | 2014-07-03 | Guriqbal S. Basi | Compositions and methods for treating diseases of protein aggregation involving ic3b deposition |
| EP2515112B1 (en) | 2011-04-22 | 2015-08-12 | Sysmex Corporation | Method for electrochemically detecting analyte |
| JP5795184B2 (ja) | 2011-04-22 | 2015-10-14 | 国立大学法人 奈良先端科学技術大学院大学 | 被検物質の電気化学的検出方法 |
| US20140348865A1 (en) | 2011-09-12 | 2014-11-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Ser. | Immunogens based on an hiv-1 v1v2 site-of-vulnerability |
| WO2013044203A2 (en) | 2011-09-23 | 2013-03-28 | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPTARTMENT OF HEALTH & HUMAN SERVICES | Novel influenza hemagglutinin protein-based vaccines |
| EP2877205A4 (en) | 2012-07-26 | 2016-04-06 | Jackson H M Found Military Med | VACCINE WITH A MULTIMED FUSION PROTEIN AND IMMUNOTHERAPY |
| EP3054971B1 (en) | 2013-10-11 | 2021-03-10 | The United States of America, represented by the Secretary, Department of Health and Human Services | Epstein-barr virus vaccines |
| CZ2014320A3 (cs) | 2014-05-09 | 2015-11-18 | VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. | Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy |
| US10363301B2 (en) * | 2014-05-27 | 2019-07-30 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Stabilized influenza hemagglutinin stem region trimers and uses thereof |
| US9703095B2 (en) | 2015-01-05 | 2017-07-11 | Edward Pakhchyan | Light modulator for MEMS display |
| US10301377B2 (en) * | 2015-02-24 | 2019-05-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use |
| MX2018006785A (es) | 2015-12-04 | 2018-11-09 | Dana Farber Cancer Inst Inc | Vacunacion con el dominio alfa 3 de mica/b para el tratamiento del cancer. |
| CN109310749B (zh) | 2016-06-07 | 2022-09-23 | 德国癌症研究中心 | Hpv l2肽免疫原性的改善 |
| KR102724939B1 (ko) | 2016-06-17 | 2024-11-01 | 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 | 선형 또는 분지형 폴리아크릴산 폴리머 아쥬반트를 포함하는 신규한 면역원성 제형 |
| EP3474893A1 (en) | 2016-06-27 | 2019-05-01 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens |
| EP3612562A2 (en) | 2017-04-19 | 2020-02-26 | Institute for Research in Biomedicine | Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to |
| MA50813A (fr) | 2017-11-21 | 2020-09-30 | Modernatx Inc | Vaccins contre le virus d'epstein-barr |
| CN112584858A (zh) | 2018-04-03 | 2021-03-30 | 赛诺菲 | 抗原性ospa多肽 |
| EP3773698A1 (en) | 2018-04-03 | 2021-02-17 | Sanofi | Ferritin proteins |
| JP2021519600A (ja) | 2018-04-03 | 2021-08-12 | サノフイSanofi | 抗原性インフルエンザ−フェリチンポリペプチド |
| CN112512566A (zh) | 2018-04-03 | 2021-03-16 | 赛诺菲 | 抗原性爱泼斯坦-巴尔病毒多肽 |
| JP7614841B2 (ja) | 2018-04-03 | 2025-01-16 | サノフイ | 抗原性呼吸器合胞体ウイルスポリペプチド |
-
2019
- 2019-04-02 JP JP2020554448A patent/JP7614841B2/ja active Active
- 2019-04-02 AU AU2019247034A patent/AU2019247034B2/en active Active
- 2019-04-02 WO PCT/US2019/025387 patent/WO2019195291A1/en not_active Ceased
- 2019-04-02 MX MX2020010199A patent/MX2020010199A/es unknown
- 2019-04-02 CN CN201980036093.4A patent/CN112512567A/zh active Pending
- 2019-04-02 CA CA3095175A patent/CA3095175A1/en active Pending
- 2019-04-02 EP EP19718031.8A patent/EP3773704A1/en active Pending
- 2019-04-02 BR BR112020019938-9A patent/BR112020019938A2/pt unknown
- 2019-04-02 KR KR1020207031417A patent/KR102964264B1/ko active Active
-
2020
- 2020-10-01 US US17/061,065 patent/US12071454B2/en active Active
-
2024
- 2024-07-17 US US18/775,573 patent/US20250059240A1/en active Pending
- 2024-09-06 JP JP2024153695A patent/JP2024170566A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006104216A (ja) | 1993-08-20 | 2006-04-20 | Government Of The Us Of America As Represented By The Secretary Department Of Health & Human Service | 植物、動物、およびヒトのワクチンとして並びに免疫療法に有用な抗体の免疫優性エピトープの弱化 |
| JP2014530003A (ja) | 2011-09-20 | 2014-11-17 | モウント シナイ スクール オフ メディシネ | インフルエンザウイルスワクチン及びその使用 |
| JP2016519658A (ja) | 2013-03-13 | 2016-07-07 | アメリカ合衆国 | 融合前rsvfタンパク質およびそれらの使用 |
| WO2017172890A1 (en) | 2016-03-29 | 2017-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Substitutions-modified prefusion rsv f proteins and their use |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019195291A1 (en) | 2019-10-10 |
| JP2021519597A (ja) | 2021-08-12 |
| RU2020135568A (ru) | 2022-05-06 |
| CA3095175A1 (en) | 2019-10-10 |
| MX2020010199A (es) | 2021-01-08 |
| US12071454B2 (en) | 2024-08-27 |
| BR112020019938A2 (pt) | 2021-01-26 |
| KR102964264B1 (ko) | 2026-05-13 |
| US20250059240A1 (en) | 2025-02-20 |
| AU2019247034A1 (en) | 2020-10-22 |
| US20210017237A1 (en) | 2021-01-21 |
| KR20210018206A (ko) | 2021-02-17 |
| JP2024170566A (ja) | 2024-12-10 |
| EP3773704A1 (en) | 2021-02-17 |
| CN112512567A (zh) | 2021-03-16 |
| AU2019247034B2 (en) | 2025-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024170566A (ja) | 抗原性呼吸器合胞体ウイルスポリペプチド | |
| US11904009B2 (en) | Ferritin proteins | |
| US12121562B2 (en) | Antigenic Epstein Barr virus polypeptides | |
| US11993636B2 (en) | Antigenic OspA polypeptides | |
| US20230241199A1 (en) | Protein-based nanoparticle vaccine for metapneumovirus | |
| JP2021519600A (ja) | 抗原性インフルエンザ−フェリチンポリペプチド | |
| JP2025063151A (ja) | 抗原性多量体呼吸器合胞体ウイルスポリペプチド | |
| RU2807992C2 (ru) | Антигенные полипептиды на основе последовательности респираторно-синцитиального вируса | |
| RU2816208C2 (ru) | АНТИГЕННЫЕ ПОЛИПЕПТИДЫ НА ОСНОВЕ ПОСЛЕДОВАТЕЛЬНОСТИ OspA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210525 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220330 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220330 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230224 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230314 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230613 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230911 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231128 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240228 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240507 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240906 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20240919 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20241210 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20241227 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7614841 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |